Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Conde, Esther ^a   Suárez Gauthier, Ana ^a   Benito, Amparo ^b   Garrido, Pilar ^b   García Campelo, Rosario ^c   Biscuola, Michele ^d   Paz Ares, Luis ^d   Hardisson, David ^e   De Castro, Javier ^e   Camacho, M Carmen ^f   Rodriguez Abreu, Delvys ^f   Abdulkader, Ihab ^g   Ramirez, Josep ^h   Reguart, Noemí ^h   Salido, Marta ⁱ   Pijuán, Lara ⁱ   Arriola, Edurne ⁱ   Sanz, Julián ^j   Folgueras, Victoria ^k   Villanueva, Noemí ^k   Gómez Román, Javier ^l   Hidalgo, Manuel ^a   López Ríos, Fernando ^a   more..

^a Hospital Universitario Madrid Sanchinarro   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c CHU A Coruna   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^g UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MONOCLONAL ANTIBODY; ANTIBODY; PROTEIN TYROSINE KINASE;

ARTICLE; AUTOANALYSIS; BREAK APART PROBE SET; CONTROLLED STUDY; CORRELATIONAL STUDY; DEVICE APPROVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC USE; FOOD AND DRUG ADMINISTRATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETICS; LABORATORY AUTOMATION; LUNG NEOPLASMS; PROCEDURES; UNITED STATES;

ANTIBODIES; AUTOMATION, LABORATORY; CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; SENSITIVITY AND SPECIFICITY; TRANSLOCATION, GENETIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907584497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107200     Document Type: Article

References (64)

1. Riely GJ, Chaft JE, Ladanyi M, Kris MG (2011) Incorporation of crizotinib into de NCCN guidelines. J Natl Compr Can Netw 9: 1328-1330.
2. European Medicines Agency. Available: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002489/WC500134761.pdf. Accessed 2013 July 21.
3. Gridelli C, Solange P, Sgambato A., Casaluce F, Adjei AA, et al. (2014) ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 40: 300-306.
4. Wolff AC, Hammond ME, Hicks D.G., Dowsett M., McShane LM, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31: 3997-4013.
5. Sauter G, Lee J, Bartlett J.M., Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27: 1323-1333.
6. De P, Smith BR, Leyland-Jones B (2010) Human epidermal growth factor receptor 2 testing: where are we? J Clin Oncol 28: 4289-4292.
7. Karachaliou N, Rosell R (2013) Optimal detection of ALK rearranged lung adenocarcinomas. J Thorac Oncol 8: 255-256.
8. Kim H, Xu X, Yoo S.B., Sun PL, Jin Y, et al. (2013) Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases. Histopathology 62: 305-314.
9. Sholl LM, Weremowicz S, Gray S.W., Wong KK, Chirieac LR, et al. (2013) Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 8: 322-328.
10. Han XH, Zhang NN, Ma L, Lin D.M., Hao XZ, et al. (2013) Immunohisto-chemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch 463: 583-591.
11. Ying J, Guo L, Qiu T., Shan L, Ling Y, et al. (2013) Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol 24: 2589-2593.
12. Wu YC, Chang IC, Wang C.L., Chen TD, Chen YT, et al. (2013) Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan. PLoS One 8: e70839.
13. Li Y, Pan Y, Wang R., Sun Y, Hu H, et al. (2013) ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR. PLoS One 8: e69016.
14. Minca EC, Portier BP, Wang Z, Lanigan C., Farver CF, et al. (2013) ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 15: 341-346.
15. Shaw AT, Kim DW, Mehra R, Tan D.S., Felip E., et al. (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370: 1189-1197.
16. Takamochi K, Takeuchi K, Hayashi T., Oh S, Suzuki K (2013) A Rational Diagnostic Algorithm for the Identification of ALK Rearrangement in Lung Cancer: A Comprehensive Study of Surgically Treated Japanese Patients. PLoS One 8: e69794.
17. Murakami Y, Mitsudomi T, Yatabe Y (2012) A Screening Method for the ALK Fusion Gene in NSCLC. Front Oncol 2: 1-9.
18. Nitta H, Tsuta K, Yoshida A., Ho SN, Kelly BD, et al. (2013) New Methods for ALK Status Diagnosis in Non-Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC-In Situ Hybridization Assay. J Thorac Oncol 8: 1019-1031.
19. Travis WD, Brambilla E, Müller-Hermelink HK, Curtis CH (2004) WHO Classification. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press.
20. Travis WD, Brambilla E, Noguchi M., Nicholson AG, Geisinger KR, et al. (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
21. BioView. Available: http://www.bioview.co.il/HTMLs/page-70.aspx?c0=12677&bsp=12624&bss53=12640. Accessed 2014 May 14.
22. Thunnissen E, Bubendorf L, Dietel M., Elmberger G, Kerr K, et al. (2012) EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 461: 245-257.
23. Conde E, Angulo B, Izquierdo E., Muñoz L, Suárez-Gauthier A, et al. (2013) The ALK translocation in advanced non-small-cell lung carcinomas: pre-approval testing experience at a single cancer centre. Histopathology 62: 609-616.
24. Zhang NN, Liu YT, Ma L, Wang L., Hao XZ, et al. (2014) The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. PLoS One 9: e84501.
25. Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, et al. (2011) Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 6: 21-27.
26. Rodig SJ, Mino-Kenudson M, Dacic S., Yeap BY, Shaw A, et al. (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216-5223.
27. Yoshida A, Tsuta K, Nakamura H., Kohno T, Takahashi F, et al. (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35: 1226-1234.
28. Nishino M, Klepeis VE, Yeap B.Y., Bergethon K., Morales-Oyarvide V, et al. (2012) Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 25: 1462-1472.
29. Cabillic F, Gros A, Dugay F., Begueret H, Mesturoux L, et al. (2014) Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances. J Thorac Oncol 9: 295-306.
30. Gainor JF, Varghese AM, Ou S.H., Kabraji S., Awad MM, et al. (2013) ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19: 4273-4281.
31. Yang JJ, Zhang XC, Su J, Xu C.R., Zhou Q., et al. (2014) Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation. Clin Cancer Res 20: 1383-1392.
32. Wynes MW, Sholl LM, Dietel M, Schuuring E., Tsao MS, et al. (2014) An international interpretation study using the ALK IHC antibody D5F3 and asensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 9: 631-638.
33. Caliò A, Nottegar A, Gilioli E, Bria E, Pilotto S, et al. (2014) ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. J Thorac Oncol 9: 729-732.
34. Shaw AT, Kim DW, Nakagawa K, Seto T., Crinó L, et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394.
35. Lindeman NI, Cagle PT, Beasley M.B., Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137: 828-860.
36. Nakamura H, Tsuta K, Yoshida A., Shibata T, Wakai S, et al. (2013) Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol 66: 705-706.
37. Takeuchi K (2013) Interpretation of Anti-ALK Immunohistochemistry Results. J Thorac Oncol 8: e67-e68.
38. Savic S, Bode B, Diebold J., Tosoni I, Barascud A, et al. (2013) Detection of ALK-Positive Non-Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone. J Thorac Oncol 8: 1004-1011.
39. Martinez P, Hernández-Losa J, Montero MA, Cedrés S, Castellví J, et al. (2013) Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One 8: e52261.
40. Blackhall FH, Peters S, Kerr K.M., O'Byrne KJ, Hager H, et al. (2012) Prevalence and clinical outcomes for patients with ALK positive adenocarcino-ma in Europe: preliminary results from the European Thoracic Oncology Platform Lungscape Project. ESMO.
41. Le Quesne J, Maurya M, Yancheva S.G., O'Brien M, Popat S, et al. (2014) A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. J Thorac Oncol 9: 769-74.
42. Demidova I, Barinov A, Savelov N., Gagarin I, Grinevitch V, et al. (2014) Immunohistochemistry, fluorescence in situ hybridization, and reverse tran-scription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Arch Pathol Lab Med 138: 794-802.
43. Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, et al. (2014) ALK Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescent In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. Arch Pathol Lab Med Jun 2. [Epub ahead of print] PubMed PMID: 24885803.
44. Sun JM, Choi YL, Won J.K., Hirsch FR, Ahn JS, et al. (2012). A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 7: e36-38.
45. Grimm EE, Schmidt RA, Swanson P.E., Dintzis SM, Allison KH (2010) Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol 134: 284-292.
46. Brevet M, Arcila M, Ladanyi M (2010) Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12: 169-176.
47. Tuononen K, Sarhadi VK, Wirtanen A, Rönty M, Salmenkivi K., et al. (2013) Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed Res Int 757490.
48. Dacic S (2013) Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol 66: 870-874.
49. Zhou J, Zhao J, Sun K., Wang B, Wang L, et al. (2014) Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening. PLoS One 9: e92828.
50. Paik JH, Choe G, Kim H., Choe JY, Lee HJ, et al. (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6: 466-672.
51. McLeer-Florin A, Moro-Sibilot D, Melis A., Salameire D, Lefebvre C, et al. (2012) Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 7: 348-354.
52. Fukui T, Yatabe Y, Kobayashi Y., Tomizawa K, Ito S, et al. (2012) Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 77: 319-325.
53. Paik JH, Choi CM, Kim H, Jang S.J., Choe G., et al. (2012) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 76: 403-409.
54. Wong DW, Leung EL, So K.K., Tam IY, Sihoe AD, et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723-1733.
55. Inamura K, Takeuchi K, Togashi Y., Hatano S, Ninomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508-515.
56. Conklin CM, Craddock KJ, Have C, Laskin J., Couture C, et al. (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8: 45-51.
57. Selinger CI, Rogers TM, Russell P.A., O'Toole S, Yip P et al. (2013) Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 26: 1545-1553.
58. V Laffert M, Warth A, Penzel R, Schirmacher P, Jonigk D, et al. (2013) Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing. Lung Cancer 81: 200-206.
59. To KF, Tong JH, Yeung K.S., Lung RW, Law PP et al. (2013) Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. J Thorac Oncol 8: 883-891.
60. Li T, Maus MK, Desai S.J., Beckett LA, Stephens C, et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9: 18-25.
61. Shaw AT, Varghese AM, Solomon B.J., Costa DB, Novello S, et al. (2013) Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 24: 59-66.
62. Camidge DR, Skokan M, Kiatsimkul P., Helfrich B, Lu X, et al. (2013) Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: Implications for ALK inhibitor therapy. Cancer 119: 3968-3975.
63. Proietti A, Alì G, Pelliccioni S, Lupi C, Sensi E, et al. (2014) Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: Comparison with histological assessment. Cancer Cytopathol. 122: 445-453.
64. Wallander ML, Geiersbach KB, Tripp S.R., Layfield LJ (2012) Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 136: 796-803.